|
|
Profile
|
Delegates :
Teruo Susumu |
|
Incorporated :
April 17 , 2018 |
Paid in Capital :
23 Million yen |
Employees :
4 人 |
Address :
Innovation Hub Kyoto 46-29 Yoshidashimoadachi-cho,Sakyo-ku,Kyoto KYOTO
〒606-8304
|
TEL/FAX :
75-757-6234 / |
URL：
http://acernatec.com/ |
Attachment :
|
Mission/Background :
Our company was founded in April, 2018 with the support of Kyoto University Innovation Capital (KYOTO-iCAP), Kyoto city, and Advanced Science, Technology & Management Research Institute of KYOTO (ASTEM).
We are planning to introduce "RNA Switch" technology to the market as a research reagent for the first time. The "RNA Switch" technology under an intellectual property of Center for iPS Cell Research and Application (CiRA), Kyoto University is a technology that senses an activation state of microRNA (hereinafter miRNA) in living cells. In the field of regenerative medicine, it is very important to remove contaminated undifferentiated cells that have potential to become cancer during a directed differentiation from iPS cells to specific cell types such as cardiomyocytes. The "RNA Switch" technology will provide an excellent solution to solve this issue.
|
|
Technology & Business
|
Our company was founded in April, 2018 with the support of Kyoto University Innovation Capital (KYOTO-iCAP), Kyoto city, and Advanced Science, Technology & Management Research Institute of KYOTO (ASTEM).
We are planning to introduce "RNA Switch" technology to the market as a research reagent for the first time. The "RNA Switch" technology under an intellectual property of Center for iPS Cell Research and Application (CiRA), Kyoto University is a technology that senses an activation state of microRNA (hereinafter miRNA) in living cells. In the field of regenerative medicine, it is very important to remove contaminated undifferentiated cells that have potential to become cancer during a directed differentiation from iPS cells to specific cell types such as cardiomyocytes. The "RNA Switch" technology will provide an excellent solution to solve this issue.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Sales of cell sorting reagents for research, provision of medical RNA switch
|
Discovery
|
It aims to introduce cell sorting reagent to the market. Ultimately, we will aim for market in regenerative medicine field for t
|
Sales of cell selection reagents
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
In addition to collaborating with Saito laboratory of iPS cell laboratory, concrete consultation towards providing RNA switch for regenerative medicine will be started soon.
|
|
Alliance strategy
|
In particular, I would like a proactive alliance regarding the following.
・On the sales channels of products in the sales business of cell sorting reagent products
・Business tie-ups on selection of target cells that were induced to differentiate from iPS cells or ES cells, collaborative research
|
|
|